Danazol therapy renders red cells resistant to osmotic lysis
Other
OA: closed
CC0
⤵ 7 in-corpus citations
AI-generated summary
Danazol therapy directly altered red cell membranes, increasing their surface area and resistance to osmotic lysis, as evidenced by target cell formation and reduced osmotic fragility.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Danazol, an attenuated androgen, is useful in endometriosis, idiopathic thrombocytopenic purpura (ITP), and autoimmune hemolytic anemia (AIHA). However, its mechanism of action is unknown. We investigated the possibility that danazol affects cell membranes directly. Red cell osmotic fragility was studied in patients receiving danazol. A significant decrease in osmotic fragility was observed. Accompanying the change, peripheral blood smears showed many target cells and electron microscopy revealed extra folds in erythrocyte membranes. Twenty-two patients were studied prospectively before and after danazol. Osmotic fragility decreased significantly (P less than 0.001) in 1 month of therapy and progressed with further treatment. A rebound increase (P less than 0.01) was observed in 1 month after discontinuation of danazol among 16 patients. Incubation experiments showed that danazol-induced changes are not reversed with normal sera. Patient sera did not induce the changes in normal red cells. Danazol in vitro protected red cells from osmotic lysis at low concentrations but enhanced lysis at high concentrations. We suggest that danazol alters red cell membranes directly to increase their surface area, inducing target cell formation and increasing their resistance to osmotic lysis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (22)
- Cholesterol, high density lipoprotein and danazol via openalex
- Danazol binding to steroid receptors in human uterine endometrium via openalex
- Danazol in idiopathic thrombocytopenic purpura via openalex
- Effects of danazol on plasma lipid and lipoprotein levels in healthy women and in women with endometriosis via openalex
- Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women via openalex
- Short-term effects of danazol on endometrial histology via openalex
- [Treatment of paroxysmal nocturnal hemoglobinuria with danazol] via openalex
- Treatment of sickle cell disease with danazol via openalex
- W2092558207 via openalex
- W2118832530 via openalex
- W2138573914 via openalex
- W2271112592 via openalex
- W2320457468 via openalex
- W2323819712 via openalex
- W2486128797 via openalex
- W1967190216 via openalex
- W1998336017 via openalex
- W2016782194 via openalex
- W2045004941 via openalex
- W2058767917 via openalex
- W2067281595 via openalex
- W2071599698 via openalex
Cited by (6)
- Efectos del danazol y hemisuccinato de danazol sobre la presión de perfusión y resistencia vascular 2010
- Monitoring of CD59 expression in paroxysmal nocturnal hemoglobinuria treated with danazol 2001
- Danazol for paroxysmal nocturnal hemoglobinuria 1997
- Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases 1996
- Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol 1991
- Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women 1989
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-10-08T21:20:50.926721+00:00
License: CC0
· commercial use OK